Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Alba

Showing results (91-100 of 120) with videos related to

Pageof 12
Sort By:
Medicina Clinica|June 20, 2001
[Clinical pattern and therapeutic results obtained in Germ-Cell testicular cancer in Spain based on a consecutive series of 1250 patients]J R Germà, X García Del Muro, P Maroto, et al.
BMC Cancer|October 30, 2016
Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapyJ Gomez-Millan, B Pajares, L Perez-Villa, et al.
Actas Urologicas Espanolas|September 7, 2021
Hemorrhagic complicationes after percutaneous nephrolithotomy: The importance of an early endovascular managementA Alabat Roca, C Torrecilla Ortíz, J M Cuadrado Campaña, et al.
British Journal of Cancer|May 3, 2002
Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclinesD C Talbot, V Moiseyenko, S Van Belle, et al.
Actas Urologicas Espanolas|November 12, 2021
Hemorrhagic complicationes after percutaneous nephrolithotomy: The importance of an early endovascular managementA Alabat Roca, C Torrecilla Ortíz, J M Cuadrado Campaña, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 3, 2013
Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patientsA Sánchez-Muñoz, Y Plata-Fernández, M Fernández, et al.
Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy|December 25, 2022
Red fluorescent benzothiadiazole derivative loaded in different nanoformulations: Optical properties and their use in bio-imagingV Alvarez-Venicio, R Castro-Beltrán, G Ramos-Ortiz, et al.
Orphanet Journal of Rare Diseases|December 21, 2024
Minimal encephalopathy in hereditary hemorrhagic telangiectasia patients with portosystemic vascular malformationsB Villanueva, A Cañabate, R Torres-Iglesias, et al.
Journal of Surgical Oncology|November 29, 2023
United States insurance coverage of immediate lymphatic reconstructionOkensama La-Anyane, Brandon E Alba, Kelly A Harmon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 8, 2012
Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II studyE Alba, L Calvo, J Albanell, et al.
Pageof 12

Showing results (91-100 of 120) with videos related to

Sort By:
Pageof 12
Medicina Clinica|June 20, 2001
[Clinical pattern and therapeutic results obtained in Germ-Cell testicular cancer in Spain based on a consecutive series of 1250 patients]J R Germà, X García Del Muro, P Maroto, et al.
BMC Cancer|October 30, 2016
Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapyJ Gomez-Millan, B Pajares, L Perez-Villa, et al.
Actas Urologicas Espanolas|September 7, 2021
Hemorrhagic complicationes after percutaneous nephrolithotomy: The importance of an early endovascular managementA Alabat Roca, C Torrecilla Ortíz, J M Cuadrado Campaña, et al.
British Journal of Cancer|May 3, 2002
Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclinesD C Talbot, V Moiseyenko, S Van Belle, et al.
Actas Urologicas Espanolas|November 12, 2021
Hemorrhagic complicationes after percutaneous nephrolithotomy: The importance of an early endovascular managementA Alabat Roca, C Torrecilla Ortíz, J M Cuadrado Campaña, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 3, 2013
Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patientsA Sánchez-Muñoz, Y Plata-Fernández, M Fernández, et al.
Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy|December 25, 2022
Red fluorescent benzothiadiazole derivative loaded in different nanoformulations: Optical properties and their use in bio-imagingV Alvarez-Venicio, R Castro-Beltrán, G Ramos-Ortiz, et al.
Orphanet Journal of Rare Diseases|December 21, 2024
Minimal encephalopathy in hereditary hemorrhagic telangiectasia patients with portosystemic vascular malformationsB Villanueva, A Cañabate, R Torres-Iglesias, et al.
Journal of Surgical Oncology|November 29, 2023
United States insurance coverage of immediate lymphatic reconstructionOkensama La-Anyane, Brandon E Alba, Kelly A Harmon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 8, 2012
Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II studyE Alba, L Calvo, J Albanell, et al.
Pageof 12